Welcome, Guest. Please login or register.
August 16, 2018, 11:36:15 am

Login with username, password and session length


Members
Stats
  • Total Posts: 734398
  • Total Topics: 60559
  • Online Today: 313
  • Online Ever: 1421
  • (August 13, 2016, 05:18:44 am)
Users Online

Welcome


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Switching to Symtuza Is Safe and Effective  (Read 231 times)

0 Members and 1 Guest are viewing this topic.

Offline JimDublin

  • Administrator
  • Member
  • Posts: 9,071
  • Twitter @JimAllenDublin
    • HIV Lessons
Switching to Symtuza Is Safe and Effective
« on: July 31, 2018, 05:06:46 pm »
Well good results

Quote
Janssen’s newly approved single-tablet antiretroviral (ARV) regimen Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) is safe and effective for those with fully suppressed HIV who switch from another boosted protease inhibitor–based regimen, regardless of the previous regimen.

Researchers presented findings from the Phase III randomized noninferiority trial of switching to Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) from a boosted protease inhibitor–based regimen at the International AIDS Conference in Amsterdam (AIDS 2018).

Of the 1,141 people enrolled in the study, 70 percent were taking Prezista (darunavir) at the study’s outset while 30 percent were taking Reyataz (atazanavir) or lopinavir. Eighty-five percent were taking Norvir (ritonavir) as a booster while 15 percent were taking Tybost (cobicistat). All those on lopinavir took it with Norvir as a booster, meaning they were taking Kaletra (lopinavir/ritonavir).

Fifty-eight percent of the participants had previously taken at least five ARVs and 15 percent had previously experienced virologic failure.

The participants were randomized to stay on their current regimen or switch to Symtuza. After 48 weeks of treatment, 95 percent of those who switched to Symtuza had a fully suppressed viral load, compared with 94 percent of those who did not switch. One percent of each group experienced virologic failure, defined as either a viral load of 50 or above or stopping treatment early with a viral load above that threshold.

When the study authors broke down the findings according to the different regimens the participants took at the study’s outset, they found comparable results. No one developed drug resistance to any of the ARVs used in the study.
HIV 101 - Everything you need to know
HIV 101
Transmission and Risks:
HIV Transmission and Risks
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

Offline Mightysure

  • Member
  • Posts: 377
Re: Switching to Symtuza Is Safe and Effective
« Reply #1 on: August 09, 2018, 01:16:24 pm »
Id avoid this one if I was taking any other medication. Cobicistat causes too many interactions with other meds.

 


Terms of Membership for these forums
 

© 2018 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.